Medline (NASDAQ:MDLN) Research Coverage Started at UBS Group

UBS Group initiated coverage on shares of Medline (NASDAQ:MDLN) in a research note published on Monday, Marketbeat reports. The brokerage issued a buy rating and a $48.00 target price on the stock.

Several other brokerages have also commented on MDLN. Mizuho began coverage on Medline in a report on Monday. They issued an “outperform” rating and a $48.00 price objective for the company. The Goldman Sachs Group began coverage on Medline in a research report on Monday. They issued a “buy” rating and a $49.00 target price on the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of Medline in a research report on Monday. They set a “hold” rating and a $40.00 price target for the company. William Blair began coverage on shares of Medline in a report on Monday. They issued an “outperform” rating on the stock. Finally, Bank of America began coverage on shares of Medline in a report on Monday. They set a “buy” rating and a $50.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Medline presently has an average rating of “Moderate Buy” and a consensus target price of $46.70.

Medline Trading Up 1.3%

Shares of MDLN stock opened at $43.41 on Monday. Medline has a 12-month low of $34.89 and a 12-month high of $45.50.

Insider Activity at Medline

In other news, Director Andrew J. Mills purchased 2,586,206 shares of the stock in a transaction on Thursday, December 18th. The shares were acquired at an average price of $29.00 per share, with a total value of $74,999,974.00. Following the completion of the acquisition, the director directly owned 2,586,206 shares of the company’s stock, valued at $74,999,974. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Charles N. Mills purchased 2,579,310 shares of the company’s stock in a transaction on Thursday, December 18th. The stock was purchased at an average price of $29.00 per share, with a total value of $74,799,990.00. Following the completion of the transaction, the director owned 2,441,379 shares of the company’s stock, valued at approximately $70,799,991. This trade represents a -1,870.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Several major brokers initiated bullish coverage or set high price targets (Truist $52, Evercore $50, BTIG $50, Goldman $49, Sanford Bernstein $49, UBS $48, RBC $47, BMO $45, Leerink/Baird strong-buy). Those reports signal upward earnings/market-share expectations and provide concrete upside targets for investors, supporting the rally. Analyst Coverage & Targets (Benzinga)
• Neutral Sentiment: Widespread coverage initiations across big banks (Deutsche Bank, Jefferies, Wells Fargo, JPMorgan, Citigroup, Barclays, Mizuho, TD Cowen, Wolfe Research, Rothschild/Redburn, BNP Paribas Exane) increase the stock’s visibility and institutional research footprint—likely to lift liquidity and investor interest over time but not an immediate fundamental change on its own. Coverage Initiations (AmericanBankingNews)
• Neutral Sentiment: Press coverage highlighting a strong market debut and “aging dividend” thematic interest has helped momentum traders and retail investors take notice; this amplifies the technical lift but is not new company-specific fundamental news. Market Debut Coverage (NAI500)
• Negative Sentiment: Not all firms are uniformly bullish—BNP Paribas and Rothschild/Redb issued “hold” ratings for now. These more cautious views could cap near-term upside if other analysts temper forecasts or if results miss elevated expectations. Hold Ratings (Zacks)

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.